
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic is acquiring Scientia Vascular for $550M, which complements its existing Neurovascular business and expands its product portfolio in a fragmented market. This acquisition is expected to be minimally dilutive to adjusted EPS in FY27 and accretive thereafter, and demonstrates MDT's strategy of pursuing tuck-in acquisitions for stronger organic growth. With a deep product pipeline driving revenue growth and potential margin improvement, MDT is positioned for high-single digit EPS growth, but inconsistent execution and quarterly results may prevent P/E multiple expansion.
Bears say
Medtronic is currently facing a negative outlook due to unsuccessful new product launches and potential market share loss in certain product categories. This, combined with flat or declining operating margins, may result in below-consensus earnings. Additionally, the company's non-GAAP gross and operating margins have been down year-over-year as unfavorable mix, tariffs, and costs offset favorable currency, pricing, and operating expense leverage. However, there is potential for a strong product cycle in the future, which could lead to improved organic revenue growth and earnings.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares